Melanoma Diagnostics
Castle Biosciences Q1 Revenues Grow 18 Percent
The Friendswood, Texas-based molecular diagnostics company reported revenues of $26.9 million in Q1 2022, up from $22.8 million a year ago.
Castle Biosciences Q4 Revenues Grow 45 Percent
The molecular diagnostics company said it delivered 33 percent more DecisionDx-Melanoma test results in Q4 2021 than in the previous year's fourth quarter.
Castle Biosciences Receives New York State Approval for DecisionDx DiffDx-Melanoma Test
The gene expression profile assay is meant to aid dermatopathologists in characterizing difficult-to-diagnose melanocytic lesions.
Castle Biosciences Awarded VA Supply Contract for Melanoma Test
The company said the contract will provide greater access to its DecisionDx-Melanoma gene expression profile test for veterans and active duty military.
Reporting 27 Percent Q3 Jump, Myriad Outlines Three-Pronged Plan for Diversifying Revenue Base
Premium
After reporting a 27 percent increase in its fiscal third quarter revenues, Myriad Genetics this week outlined three strategic directives for diversifying its revenue base, including growing sales of its existing tests in the US, launching new tests and companion diagnostics in a